Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about MERCK AND COMPANY
03:29p MERCK AND : FDA Accepts Supplemental Biologics License Application (sBLA), Assig..
02:11p MERCK AND : Neon Therapeutics Announces Clinical Trial Collaboration with Merck
01:27p Merck raises stakes in lung cancer as rivals close in
12:38p MERCK AND : FDA Accepts Supplemental Biologics License Application (sBLA), Assig..
07:32a ROCHE : Tecentriq cocktail slows kidney cancer progression
12/08 MERCK AND : New England Journal of Medicine Publishes Phase 3 Clinical Study of ..
12/07 Sage Therapeutics, Dollar General jump; LendingClub tumbles
12/07 Roche drug cocktail doubles chance of holding lung cancer at bay
12/07 DOW MOVERS : Jpm, mrk
12/07 U.K. unveils life sciences sector deal
12/06 MERCK AND : New England Journal of Medicine Publishes Phase 3 Clinical Study of ..
12/06 Roche to seize leap-frog opportunity in lung cancer
12/06 GSK, other drugmakers bet on post-Brexit UK science
12/01 MERCK AND : Commemorates 30 Years of MECTIZAN Donation Program Progress
12/01 MERCK AND : New and Updated Data for Merck's KEYTRUDA and Updated Data on LYNPAR..
More most relevant news
All news about MERCK AND COMPANY
03:29p MERCK AND : FDA Accepts Supplemental Biologics License Application (sBLA), Assig..
02:11p MERCK AND : Neon Therapeutics Announces Clinical Trial Collaboration with Merck
01:27p Merck raises stakes in lung cancer as rivals close in
12:38p MERCK AND : FDA Accepts Supplemental Biologics License Application (sBLA), Assig..
07:32a ROCHE : Tecentriq cocktail slows kidney cancer progression
12/09 EISAI : Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Comb..
12/08 MERCK AND : New England Journal of Medicine Publishes Phase 3 Clinical Study of ..
12/07 Sage Therapeutics, Dollar General jump; LendingClub tumbles
12/07 Roche drug cocktail doubles chance of holding lung cancer at bay
12/07 DOW MOVERS : Jpm, mrk
More news
Sector news : Pharmaceuticals - NEC
06:52p Monsanto offers cash to U.S. farmers who use controversial chemical
05:18p ASTRAZENECA : GSK's new pharma head on lookout for cancer deals to boost pipelin..
01:45pDJSANOFI : Urges Philippines to Lift Dengue Vaccine Suspension -AFP
01:27p Merck raises stakes in lung cancer as rivals close in
07:45aDJROCHE : Reports Positive Results From IMmotion151 Kidney Cancer Trial
07:32a ROCHE : Tecentriq cocktail slows kidney cancer progression
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01:01p FDA accepts Merck's marketing application for Keytruda for type of lymphoma; ..
12:13p Roche Delivers Some Clinical Wins, But Skepticism Remains Largely Intact
12/10 BIOTECH IN 2018 : Will Repatriated Cash Fuel A Feeding Frenzy?
12/08 Halaven/Keytruda combo shows 26% response rate in TNBC study
12/08 73 Dividend Growth Stocks Going Ex-Dividend Next Week
12/06 Merck weak ahead of Roche data release from late-stage study of Tecentriq in ..
Financials ($)
Sales 2017 40 235 M
EBIT 2017 13 721 M
Net income 2017 5 246 M
Debt 2017 13 787 M
Yield 2017 3,40%
P/E ratio 2017 27,22
P/E ratio 2018 17,87
EV / Sales 2017 4,11x
EV / Sales 2018 3,99x
Capitalization 152 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 65,4 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-7.68%151 559
JOHNSON & JOHNSON21.23%377 698
NOVARTIS11.34%218 728
PFIZER9.48%213 036
ROCHE HOLDING LTD.6.19%208 877
AMGEN18.98%127 332